Trials / Conditions / Pure Red Cell Aplasia

Pure Red Cell Aplasia

15 registered clinical trials studyying Pure Red Cell Aplasia — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	The Use of Trifluoperazine in Transfusion Dependent DBA NCT03966053	Adrianna Vlachos, MD	Phase 1 / Phase 2
Unknown	Tacrolimus Treatment for Refractory Autoimmune Cytopenia NCT03918265	Peking Union Medical College Hospital	Phase 4
Unknown	Tacrolimus Treatment for Refractory PRCA NCT03540472	Peking Union Medical College Hospital	Phase 4
Completed	Sirolimus Treatment for Refractory PRCA NCT03364764	Bing Han	Phase 4
Recruiting	Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and a Major ABO-Incompatible Matche NCT03214354	University of Calgary	Phase 2
Completed	Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Black NCT01362595	Northwell Health	Phase 1 / Phase 2
Recruiting	National Registry of Rare Kidney Diseases NCT06065852	UK Kidney Association	—
Completed	Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney NCT00391287	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	—
Completed	Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney D NCT00314795	Takeda	Phase 2
Completed	A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Ch NCT00211068	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	—
Completed	A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment NCT00211042	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	—
Unknown	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases NCT00006055	Fairview University Medical Center	N/A
Terminated	A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure NCT00001962	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
Completed	Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syn NCT00004143	David Rizzieri, MD	Phase 2
Completed	Stem Cell Transplantation (SCT) for Genetic Diseases NCT00004378	National Center for Research Resources (NCRR)	N/A